A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

Alexa Vyain Zhao1*, Rustin D. Crutchley2, Rakesh Chowdary Guduru3, Kathy Ton4, Tammie Lam5 and Amy Cheng Min6

Abstract
Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve individuals living with HIV; these include first generation raltegravir, elvitegravir, and second generation dolutegravir and bictegravir. The most recent INSTI, cabotegravir, is approved for (1) treatment of HIV infection in adults to replace current antiretroviral therapy in individuals who maintain virologic suppression on a stable antiretroviral regimen without history of treatment failure and no known resistance to its components and (2) pre-exposure prophylaxis in individuals at risk of acquiring HIV-1 infection. Cabotegravir can be administered intramuscularly as a monthly or bi-monthly injection depending on the indication. This long-acting combination has been associated with treatment satisfaction in clinical studies and may be helpful for individuals who have difficulty taking daily oral medications. Worldwide, second generation INSTIs are preferred for treatment-naïve individuals. Advantages of these INSTIs include their high genetic barrier to resistance, limited drug-drug interactions, excellent rates of virologic suppression, and favorable tolerability. Few INSTI resistance-associated mutations have been reported in clinical trials involving dolutegravir, bictegravir and cabotegravir. Other advantages of specific INSTIs include their use in various populations such as infants and children, acute HIV infection, and individuals of childbearing potential. The most common adverse events observed in clinical studies involving INSTIs included diarrhea, nausea, insomnia, fatigue, and headache, with very low rates of treatment discontinuation versus comparator groups. The long-term clinical implications of weight gain associated with second generation INSTIs dolutegravir and bictegravir warrants further study. This review summarizes key clinical considerations of INSTIs in terms of clinical pharmacology, drug-drug interactions, resistance, and provides perspective on clinical decision-making. Additionally, we summarize major clinical trials evaluating the efficacy and safety of INSTIs in treatment-naïve patients living with HIV as well as individuals at risk of acquiring HIV infection.

Keywords: Bictegravir, Cabotegravir, Dolutegravir, Elvitegravir, HIV, Integrase strand transfer inhibitor (INSTI), Pre-exposure prophylaxis, Raltegravir, Treatment naïve

Background
Extraordinary progress has been made over the past two decades in the treatment of human immunodeficiency virus (HIV). The HIV population demographics have shifted to an aging population, especially in developed countries. This dynamic can be attributed to the development of newer antiretroviral (ARV) classes such as
integrase strand transfer inhibitors (INSTIs) and their availability as fixed-dose, co-formulated, single tablet, once daily products. These newer agents are characterized by excellent efficacy, better tolerability, and a majority having fewer drug-drug interactions (DDIs) than non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based regimens. Given these favorable properties of INSTIs, this has led to better adherence and treatment outcomes. The role of INSTIs is particularly important in an aging HIV population with increased comorbidities and likelihood of polypharmacy. In addition, INSTIs are now being recommended worldwide in most countries as a first-line treatment for people living with HIV [1].

Treatment of HIV in individuals who are newly diagnosed with HIV (treatment-naïve) usually includes two nucleoside reverse transcriptase inhibitors (NRTIs) as backbone therapy in combination with either an INSTI, NNRTI, or a boosted PI. Recommendations on which ARV regimens are preferred for treatment-naïve individuals living with HIV are included in major standard guidelines such as the Department of Health and Human Services (DHHS), British HIV Association, European AIDS Clinical Society (EACS), and World Health Organization (WHO). Most of these guidelines recommend using INSTI-based antiretroviral therapy (ART) as a preferred option for treatment of people living with HIV [1–4]. Several clinical studies have shown INSTIs to be superior to NNRTI and PI comparative treatment groups [5–8].

To describe the evolution of INSTIs, a timeline of the approval history of each INSTI product by the U.S. Food and Drug Administration (FDA) for both HIV-1 treatment and prevention is illustrated in Fig. 1. Raltegravir (RAL; Isentress\textsuperscript{®}) was the first INSTI approved by the FDA for the treatment of individuals with HIV. Twice daily dosing has been problematic for some individuals, but with the approval of the 600 mg high-dose tablet (Isentress HD\textsuperscript{®}) in 2017, this allowed for once daily dosing with RAL, albeit with two tablets to achieve a daily dose of 1200 mg. Other advantages of this ARV include fewer drug-drug interactions because of its metabolism primarily mediated by uridine diphosphate glucuronosyltransferase (UGT1A1) [9], approved indication in children living with HIV as early as birth, and availability in multiple various dosage formulations. Following in 2012, elvitegravir (EVG) was approved for the treatment of individuals with HIV. EVG undergoes metabolism predominantly by cytochrome P450 (CYP) enzymes and reaches adequate concentrations ideal for once-daily dosing when combined with a potent CYP3A4 inhibitor. For this reason, this ARV is used together with cobicistat (COBI; Tybost\textsuperscript{®}), an alternative pharmacoenhancer/booster to ritonavir (RTV; Norvir\textsuperscript{®}), to increase its concentrations [10, 11]. Because COBI has better solubility than RTV, this has allowed for increased opportunities for co-formulation with other ARVs such as EVG 150 mg/ COBI 150 mg/tenofovir disoproxil fumarate (TDF) 300 mg/ emtricitabine (FTC) 200 mg (Stribild\textsuperscript{®}) and EVG 150 mg/COBI 150 mg/tenofovir alafenamide (TAF) 10 mg/FTC 200 mg (Genvoya\textsuperscript{®}). Some disadvantages of EVG include potential for increased risk of DDIs, and similar to RAL, its characteristic low-genetic barrier to
resistance involving a single mutation and propensity for cross-resistance with RAL [12].

Dolutegravir (DTG; Tivicay®) was the next approved INSTI in 2013. Advantages of DTG include its small pill size, approved indication for use as a dispersible tablet for oral suspension in infants living with HIV as young as four weeks of age and weighing at least 3 kg, high genetic barrier to resistance, and relatively few DDIs (primarily UGT1A1 metabolism). DTG is available in a single-tablet regimen including DTG 50 mg/abacavir (ABC) 600 mg/ lamivudine (3TC) 300 mg (Triumeq®), however some limitations of this combination's use in clinical practice include the requirement for baseline HLA-B*5701 pharmacogenetic testing with ABC. The next INSTI, bictegravir (BIC), was approved by the FDA in 2018 as the co-formulated product BIC 50 mg/TAF 25 mg/FTC 200 mg (Biktarvy®) one tablet once daily. Advantages with this combination include small pill size, high genetic barrier to resistance, few DDIs (CYP3A and UGT1A1 mediated metabolism), dual coverage of HIV and hepatitis B virus (HBV), and its co-formulation with TAF (i.e., reduced bone and renal toxicities). Another advantage includes a low-dose FDC of BIC 30 mg/TAF 15 mg/FTC 120 mg (Biktarvy PD®) one tablet once daily for children weighing at least 14 kg. Disadvantages of incorporation of TAF in this FDC include an increased risk for dyslipidemia and potentially weight gain [13].

Finally, the most recent INSTI approved by the FDA in 2021 is cabotegravir (CAB). This INSTI is unique in that CAB is the first long-acting injectable suspension. Co-packaged with the NNRTI rilpivirine (RPV), it is approved as a complete regimen (Cabenuva®) for the treatment of HIV-1 infection in adults to replace the current ART regimen in those who are virologically suppressed (HIV-1 RNA<50 copies/mL) on a stable ART regimen with no history of treatment failure and with no known or suspected resistance to either CAB or RPV [14]. Advantages of this two-drug combination includes its less frequent dosing of administration of intramuscular (IM) injections (i.e., once every two months or once a month), especially for individuals with problems maintaining adherence, its relatively high-genetic barrier to resistance, as well as its sparing of NRTIs. Some disadvantages include the use of an optional four week lead-in oral dosing (CAB 30-mg tablet; Vocabria®) together with RPV, its daily requirement for administration with a meal during the oral lead-in, the need for monthly or every two months dosing visits/injections administered by a healthcare professional, and the potential risk of resistance development in individuals unable to adhere to the administration schedule [14]. Most recently was CAB’s approval for a second indication (Apretude®): in individuals weighing ≥ 35 kg who are at risk of sexually acquiring HIV-1 infection. CAB can also be used with or without a lead-in with oral CAB for this indication. Refer to Table 1 for a summary of pertinent clinical characteristics of the INSTIs [14–33].

This article reviews current literature on the clinical pharmacology of INSTIs, discusses various topics relating to INSTI resistance, provides a comparative synopsis of INSTI characteristics, identification of clinically relevant DDIs associated with each INSTI, as well as summarizes major clinical trials evaluating efficacy and safety of INSTIs used in treatment-naïve individuals living with HIV as well as HIV pre-exposure prophylaxis (PrEP). Finally, this review will provide important clinical considerations and guidance for individuals with HIV when using and choosing between various INSTIs. A discussion of the role of INSTIs in treatment-experienced individuals living with HIV is beyond the scope of this review and the reader is encouraged to refer to other published literature [34–40].

Main text

Clinical Pharmacology

Pharmacodynamics

All INSTIs have activity against HIV-1 isolated in human peripheral blood mononuclear cells, primary monocyte and macrophage cells, as well as CD4+ T-lymphocytes. Along with NRTIs and PIs, INSTIs also have activity against HIV-2. INSTIs act at the integration step of the retroviral replication cycle, this step being a hallmark of retroviruses and the point at which the proviral state is established, ensuring permanent infection. Integration is catalyzed by integrase, one of the three enzymes encoded in the HIV-1 genome [41]. Integrase appears to act within a large functional nucleoprotein complex that contains both viral DNA and many components derived from the virus and host cell. This complex is often referred to as the intasome. It is as part of the intasome that integrase catalyzes two reactions that are required to insert the reverse-transcribed HIV DNA into the DNA of the infected host cell.

The first reaction is referred to as the “3’-processing” step and the second a “strand transfer” reaction [41, 42]. During 3’-processing, integrase removes two or three nucleotides from each 3’ end of the viral DNA. This allows for the strand transfer reaction to occur, where after import of the viral DNA into the nucleus, integrase inserts the 3’ ends of the viral DNA into the host
| INSTI Product Component(s) Drug and Strength | US Trade Name | Dosage form(s) available | FDA-Labeled Indication(s) | Can it be crushed? | Metabolism | Dosing and Administration | Daily Pill Burden | Tablet Size (mm) | Reference(s) |
|---------------------------------------------|---------------|--------------------------|---------------------------|------------------|-----------|---------------------------|-----------------|-----------------|--------------|
| BIC 50 mg FTC 200 mg TAF 25 mg              | Biktarvy®     | Oral FDC tablet Low dose alternative tablet: 30 mg BIC/120 mg FTC/15 mg TAF | HIV-1 Treatment: Adult and pediatric patients weighing > 25 kg with no ARV treatment history to replace current ARV regimen in those with HIV-1 RNA < 50 copies/mL on a stable ARV regimen with no history of treatment failure and no known resistance to its components | Conflicting evidence Note: Potentially better to dissolve in water and take immediately rather than to crush | BIC: CYP3A UGT1A1 | Adults and pediatric patients weighing at least 25 kg: 1 tablet (BIC 50 mg/FTC 200 mg/TAF 25 mg) once daily PO with or without food Pediatric patients weighing at least 14 kg and < 25 kg: 1 tablet (BIC 30 mg/FTC 120 mg/TAF 15 mg) once daily PO with or without food | 1 | 15 x 8 | [15–18] |
| CAB 30 mg                                   | Vocabria®     | Oral tablet: 30 mg | HIV-1 Treatment: Adults and adolescents 12 years of age and older weighing at least 35 kg with HIV-1 RNA < 50 copies/mL on a stable ARV regimen with no history of treatment failure and with no known or suspected resistance to CAB or RPV; indicated for short-term treatment in combination with RPV | No | CAB UGT1A1 UGT1A9 (minor) | HIV-1 Treatment: Optional oral lead-in: 1 tablet (CAB 30 mg) PO once daily in combination with 1 RPV (25 mg) tablet PO once daily with a meal for at least 28 days HIV-1 prophylaxis: Optional oral lead-in: 1 tablet (CAB 30 mg) PO once daily for at least 28 days | 1 | 14.3 x 8 | [19] |
| CAB LA 200 mg/mL                            | Apretude®     | Extended-release injectable suspension: 600 mg/3 mL | HIV-1 Prophylaxis: At-risk adults and adolescents weighing at least 35 kg for PEP to reduce the risk of sexually acquired HIV-1 infection and who have a negative HIV-1 test prior to initiating | N/A | N/A | Initiation injection: CAB LA 3 mL once (if taking oral lead-in: on last day of oral lead-in or within 3 days thereafter) at month 2 and month 3 Continuation injections: CAB LA 3 mL at month 5 and every 2 months onwards | N/A | N/A | [19] |
| INSTI Product Component(s): Drug and Strength | US Trade Name | Dosage form(s) available | FDA-Labeled Indication(s) | Can it be crushed? | Metabolism | Dosing and Administration | Daily Pill Burden | Tablet Size (mm) | Reference(s) |
|-----------------------------------------------|---------------|--------------------------|---------------------------|--------------------|------------|--------------------------|----------------|----------------|-------------|
| CAB LA 300 mg/mL plus RPV 300 mg/mL           | Cabenuva®     | Extended-release injectable suspension 400 mg/600 mg kit; CAB 400 mg/2 mL RPV 600 mg/3 mL; Extended-release injectable suspension 600 mg/900 mg kit; CAB 600 mg/3 mL RPV 900 mg/3 mL | HIV-1 Treatment: Adult and pediatric patients 12 years of age and older weighing > 33 kg to replace current ARV regimen in those with HIV-1 RNA < 50 copies/mL and a stable ARV regimen with no history of treatment failure and no known resistance to its components | N/A | Dosing Schedule for Monthly Injections: Initiation injections: CAB 600 mg (3 mL) IM and RPV 900 mg (3 mL) IM once given on last day of current ARV therapy OR oral lead-in is used. Continuation injections: CAB 400 mg (2 mL) IM and RPV 600 mg (2 mL) IM once monthly. Dosing Schedule for Every-2 Month Injections: Initiation injections: CAB 600 mg (3 mL) IM and RPV 900 mg (3 mL) IM at month 1 given on last day of current ARV therapy OR oral lead-in is used and at month 2. Continuation injections: CAB 600 mg (3 mL) IM and RPV 900 mg (3 mL) IM every 2 months onwards (starting at month 4) | N/A | N/A every 2-month injection | N/A [14] |
| DTG 50 mg                                   | Tivicay®      | Oral tablet: 10 mg 25 mg 50 mg | HIV-1 Treatment: Adults and pediatric patients aged at least 4 weeks and weighing at least 3 kg in combination with other antiretroviral agents | Yes | DTG: UGT1A1 (major), CYP3A (minor) | Adults: 1 tablet (DTG 50 mg) tablet once daily PO with or without food. Take twice daily if INSTI resistance or also taking certain UGT1A or CYP3A inducers. Pediatric: Weight based dosing (refer to prescribing information). PO with or without food. Take twice daily. Also taking certain UGT1A or CYP3A inducers. | 1 or 2 | 9 x 9 | [20] |
| DTG 50 mg 3TC 300 mg                        | Dovato®       | Oral FDC tablet           | HIV-1 Treatment: Adults with no ARV treatment history and with no known resistance to its components | Yes | Note: Crushing not recommended in product information, however if crushing is decided based on clinical judgment, add to small amount of semi-solid food or liquid, consume immediately. Study data shows virologic suppression after crushing DTG when suspending it in water or adding to small amount of semi-solid food and consuming immediately | 1 tablet (DTG 50 mg/3TC 300 mg) once daily PO with or without food. | 18.5 x 9.5 | [21–25] |
| INSTI Product Component(s): Drug and Strength | US Trade Name | Dosage form(s) available | FDA-Labeled Indication(s) | Can it be crushed? | Metabolism | Dosing and Administration | Daily Pill Burden | Tablet Size (mm) | Reference(s) |
|---------------------------------------------|--------------|--------------------------|---------------------------|---------------------|------------|---------------------------|-----------------|------------------|-------------|
| DTG 50 mg RPV 25 mg                          | Juluca®      | Oral FDC tablet          | HIV-1 Treatment: Adults to replace current ARV regimen in those with HIV-1 RNA ≤ 50 copies/ml on a stable ARV regimen for at least 6 months with no history of treatment failure and no known resistance to its components. | No                  | EVG: CYP3A (major), UGT1A1/3 (minor) | 1 tablet (DTG 90 mg/RPV 25 mg) once daily PO with a meal. Dose adjustment recommended. Take with an additional 25-mg tablet of RPV PO once daily with a meal if coadministered with rifabutin. | 1               | 14 x 7           | [26]         |
| DTG 50 mg 3TC 300 mg ABC 600 mg               | Triumeq®     | Oral FDC tablet          | HIV-1 Treatment: Adult and pediatric patients weighing > 10 kg | Yes                 | EVG: CYP3A (major), UGT1A1/3 (minor) | Adults: 1 tablet (DTG 50 mg/ABC 600 mg/3TC 300 mg) once daily PO with or without food. Pediatric: Weight based dosing (refer to prescribing information) PO with or without food. DTG dose adjustment recommended. | 1               | 22 x 11          | [24, 25, 27] |
| EVG 150 mg Cobi 150 mg FTC 200 mg TAF 10 mg   | Genvoya®     | Oral FDC tablet          | HIV-1 Treatment: Adult and pediatric patients weighing > 25 kg with no ARV treatment history or to replace current ARV regimen in those with HIV-1 RNA < 50 copies/ml on a stable ARV regimen for at least 6 months with no history of treatment failure and no known resistance to its components. | Yes                 | EVG: CYP3A (major), UGT1A1/3 (minor) | 1 tablet (EVG 150/Cobi 150/FTC 200/TAF 10 mg) once daily PO with food | 1               | 19 x 8.5         | [28–31]      |
| EVG 150 mg Cobi 150 mg FTC 200 mg TDF 300 mg  | Striaba®     | Oral FDC tablet          | HIV-1 Treatment: Adult and pediatric patients 12 years of age and older weighing > 35 kg with no ARV treatment history or to replace current ARV regimen in those with HIV-1 RNA < 50 copies/ml on a stable ARV regimen for at least 6 months with no history of treatment failure and no known resistance to its components. | Yes                 | EVG: CYP3A (major), UGT1A1/3 (minor) | 1 tablet (EVG 150/Cobi 150/FTC 200/TDF 300 mg) once daily PO with food | 1               | 20 x 10          | [29–32]      |
| INSTI Product Component(s): Drug and Strength | US Trade Name | Dosage form(s) available | FDA-Labeled Indication(s) | Can it be crushed? | Metabolism | Dosing and Administration | Daily Pill Burden | Tablet Size (mm) | Reference(s) |
|---|---|---|---|---|---|---|---|---|---|
| RAL 400 mg | Isentress® | Oral tablet: 400 mg Chewable tablet: 25 mg 100 mg this is a third available dosage form for this product | HIV-1 Treatment: Adults and pediatric patients weighing > 2 kg in combination with other antiretroviral agents | Yes | RAL: UGT1A1 Adults: 1 tablet (RAL 400 mg) twice daily PO with or without food Pediatric: Weight based dosing (refer to prescribing information) | 2 | 16 x 8.8 | [33] |
| RAL HD 600 mg | Isentress HD® | Oral tablet: 600 mg | HIV-1 Treatment: Adults and pediatric patients weighing > 40 kg in combination with other antiretroviral agents | No | | 2 tablets (RAL 600 mg x 2) once daily PO with or without food | 2 | 19 x 9.7 | [33] |

3TC lamivudine, ABC abacavir, BIC bictegravir, CAB cabotegravir, COBI cobicistat, CYP3A cytochrome P450 family 3 subfamily A, DTG dolutegravir, EVG elvitegravir, FDC fixed dose combination, FTC emtricitabine, HD high dose, HIV-1 human immunodeficiency virus type 1, IM intramuscular, INSTI integrase strand transfer inhibitor, kg kilograms, LA long-acting, mg milligrams, mL milliliters, N/A not applicable, PD pediatric dose, PO by mouth, PrEP pre-exposure prophylaxis, RAL raltegravir, RPV rilpivirine, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate, UGT1A1 uridine disphosphate glucuronosyl transferase 1A1, UGT1A9 uridine disphosphate glucuronosyl transferase 1A9
cell DNA. This integration process does not require any source of energy but requires divalent cations (such as manganese or magnesium) as cofactors for catalytic activity [43].

INSTIs can be generally characterized by a metal chelating scaffold positioned to bind two Mg\(^{2+}\) cofactors, a halogenated benzene side chain that interacts with viral DNA, and a flexible linker that connects the core scaffold to the halobenzyl side chain [44, 45]. INSTIs are understood to preferentially bind to the active site of integrase within the intasome rather than free integrase [41]. Interfering with the strand transfer reaction, the INSTI binds to the divalent cations and viral DNA, displacing the viral DNA from the active site and deactivating the intasome. Consequently, this blocking of the active site prevents integration of reverse-transcribed viral DNA into the host genome [42, 46].

Second generation INSTIs were developed with the intention of overcoming resistance observed in clinical practice with first generation INSTIs RAL and EVG, both of which have a high level of cross-resistance. Second generation INSTIs, DTG, BIC and CAB have less cross-resistance with first generation INSTIs, with DTG and BIC retaining the highest potency overall [44, 47]. It is from structural data of the INSTI-bound intasome that a greater understanding of the mode of INSTI binding has emerged, leading to chemical modifications to first-generation INSTIs and more potent compounds capable of overcoming known resistance patterns. Unlike first generation INSTIs, second generation compounds possess extended tricyclic scaffolds [48, 49]. For example, the core scaffold has been made larger in addition to attaching a third ring to increase the overall surface contact with the integrase active site, allowing for more binding stability. Additionally, the linker between the halobenzyl side chain and core scaffold was lengthened which allowed for a stronger interaction with the vDNA within the intasome [50].

An additional topic of interest lies within the differences in dissociation kinetics of various INSTIs at the molecular level. Studies investigating the second generation INSTIs DTG and BIC have shown considerably longer dissociation half-lives from the wildtype intasome complex as well as from mutant intasomes commonly observed during treatment with first generation INSTIs [51, 52]. The structural differences and prolonged binding of DTG and BIC to the intasome may contribute significantly to their durability against resistance mutations compared to first generation INSTIs [51–53].

**Pharmacokinetics**

Unlike the other INSTIs which are metabolized by both CYP3A4 and UGT1A1, RAL is primarily metabolized by hepatic glucuronidation mediated by UGT1A1 only. RAL is neither an inhibitor, inducer, nor substrate of CYP enzymes [9]. EVG is a major substrate of CYP3A and undergoes primarily oxidative metabolism by CYP3A and secondarily glucuronidation by UGT1A1/3 enzymes, and studies have shown that by coadministration with pharmacokinetic enhancers such as RTV or COBI, presystemic first-pass metabolism can be substantially reduced, allowing for maintenance of adequate trough concentrations and once daily dosing [11, 54].

DTG is primarily metabolized by UGT1A1 with minor contributions from CYP3A enzymes. It is a substrate of UGT1A1/3 and UGT1A9 enzymes including breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) drug transporters in vitro, and it inhibits organic cation transporter (OCT)2 and multidrug and toxin extrusion transporter (MATE)1 in vitro. Drugs that are inducers or inhibitors of these enzymes and transporters may affect drug concentrations of DTG [55, 56]. BIC is a substrate of CYP3A and UGT1A1 and similar to DTG, inhibits OCT2 and MATE1 in vitro, however is less potent in inhibiting OCT2 compared to DTG [57, 58]. CAB is primarily metabolized by UGT1A1 with minor contributions from UGT1A9. In vitro, it inhibits organic anion transporter (OAT)1 and OAT3 and may increase the area-under-the-curve (AUC) of medications that are substrates of OAT1/OAT3 by about 80% [59, 60]. A summary of pertinent drug-drug interactions between INSTIs and commonly prescribed comediations is included in Table 2. The reader is encouraged to refer to a recent comprehensive review for additional information related to the comparative clinical pharmacokinetics and pharmacodynamics of INSTIs [61].

**Resistance**

*Resistance within integrase region* Historically, resistance mutation development to INSTIs has focused on the involvement of well-identified mutations in the target gene, integrase. The basic mechanism of resistance within integrase is well described and generally begins with an initial mutation reducing the binding affinity of the drug, but also often reduces the fitness of the virus. Continued selective drug pressure can lead to development of secondary resistance substitutions that ultimately may improve viral fitness, resulting in an increased level of INSTI resistance [62].

For first generation INSTIs, amino acid substitutions at either Tyr143 (Y143H/R/L) or Gln148 (Q148H/R/K) or N155H plus one or more additional substitutions (i.e., L74M, E92Q, Q95K/R, T97A, E138A/K, G140A/S, V151I, G163R, H183P , Y226C/D/F/H, S230R, and D232N) leads to RAL resistance [63, 64]. Primary integrase substitutions T66A/I, E92G/Q, S147G, and Q148R cause reduced
Table 2  Summary of drug-drug interactions between INSTIs with selected coadministered drugs

| Coadministered Drug | INSTI | Effect on INSTI or Coadministered Drug Concentrations |
|---------------------|-------|------------------------------------------------------|
| Al, Mg, ± Ca-containing Antacids & Polyvalent Cation Supplements (Al, Ca, Fe, Mg, Zn, including multivitamins with minerals) | BIC, CAB, DTG, EVG/c, RAL | ↓ BIC ↔ BIC with food & Ca/Fe ↓ CAB ↓ DTG ↔ DTG with food & Ca/Fe ↓ EVG/c ↓ RAL |
| **Alpha Adrenergic Inhibitors (for Benign Prostatic Hyperplasia)** | | |
| Alfuzosin | EVG/c | ↑ alfuzosin |
| Tamsulosin | EVG/c | ↑ tamsulosin |
| Silodosin | EVG/c | ↑ silodosin |
| **Anticoagulants & antiplatelets** | | |
| Apixaban | EVG/c | ↑ apixaban |
| Clopidogrel | EVG/c | ↓ clopidogrel active metabolite, with impaired platelet inhibition expected |
| Dabigatran | EVG/c | ↑ dabigatran |
| Edoxaban | EVG/c | ↑ edoxaban |
| Prasugrel | EVG/c | ↓ prasugrel active metabolite, with no impairment of platelet inhibition expected |
| Rivaroxaban | EVG/c | ↑ rivaroxaban |
| Ticagrelor | EVG/c | ↑ ticagrelor |
| Vorapaxar | EVG/c | ↑ vorapaxar |
| Warfarin | EVG/c | ↑ or ↓ warfarin |
| **Anticonvulsants** | | |
| Carbamazepine | BIC, CAB, DTG, EVG/c, RAL | ↓ BIC ↓ CAB ↓ DTG ↑ carbamazepine, ↓ EVG & COBI ↓ or ↔ RAL |
| Eslicarbazepine | All INSTIs | ↓ INSTI, ↓ COBI |
| Ethosuximide | EVG/c | ↑ ethosuximide |
| Lamotrigine | EVG/c | No data |
| Oxlcarbazepine | BIC, DTG, CAB, EVG/c, RAL | ↓ BIC, DTG ↓ CAB ↓ EVG/c, RAL |
| Phenytoin | BIC, CAB, DTG, EVG/c, RAL | ↓ OR ↔ RAL |
| | All INSTIs | No data |
| **Antidepressants/ anxiolytics/ antipsychotics** | | |
| Aripiprazole | EVG/c | ↑ aripiprazole |
| Brexpiprazole | EVG/c | ↑ brexpiprazole |
| Cariprazine | EVG/c | ↑ cariprazine |
| Bupropion | EVG/c | ↑ or ↓ bupropion |
| Buspirone | EVG/c | ↑ buspirone |
| Fluvoxamine | EVG/c | ↑ or ↓ EVG |
| Iloperidone | EVG/c | ↑ iloperidone |
| Lumateperone | EVG/c | ↑ lumateperone |
| Lurasidone | EVG/c | ↑ lurasidone |
| Nefazodone | EVG/c | ↑ nefazodone |
Table 2 (continued)

| Coadministered Drug | INSTI | Effect on INSTI or Coadministered Drug Concentrations |
|---------------------|-------|-----------------------------------------------------|
| Olanzapine          | All INSTIs | ↔ olanzapine                                        |
|                     | EVG/c  | ↑ antipsychotic                                      |
| Other antipsychotics (CYP3A4 and/or CYP2D6 substrates (e.g., perphenazine, risperidone, thioridazine) | | |
| Pimavanserin        | EVG/c  | ↑ pimavanserin                                      |
| Pimozide            | EVG/c  | ↑ pimozide                                           |
| Quetiapine          | EVG/c  | ↑ quetiapine                                         |
| SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) | BIC, CAB, DTG, RAL | ↔ SSRI |
| TCAs (amitriptyline, desipramine, doxepin, imipramine, nortriptyline) | EVG/c  | ↑ sertraline, ↑ or ↓ other SSRI                         |
| Trazodone           | EVG/c  | ↑ trazodone                                          |
| Ziprasidone         | EVG/c  | ↑ ziprasidone                                        |
| **Antifungals**     |        |                                                     |
| Isavuconazole       | EVG/c  | ↑ isavuconazole ↑ or ↓ EVG & COBI                    |
| Itraconazole, Posaconazole, Voriconazole | EVG/c  | ↑ antifungal ↑ EVG & COBI                             |
| **Antihyperglycemic drugs** | | |
| Metformin           | BIC    | ↑ metformin                                          |
|                    | DTG    | ↑ metformin                                          |
|                    | CAB PO and IM, RAL | ↔ metformin |
| Saxagliptan         | EVG/c  | ↑ saxagliptan                                        |
| **Antibacterials**  |        |                                                     |
| Azithromycin        | All INSTIs | ↔ azithromycin                                    |
| Clarithromycin      | EVG/c  | ↑ clarithromycin, COBI                              |
| Erythromycin        | EVG/c  | ↑ erythromycin, COBI                                |
| Rifabutin           | BIC    | ↓ BIC                                               |
|                    | CAB    | ↓ CAB IM                                            |
|                    | DTG    | ↔ DTG                                               |
|                    | EVG/c  | ↑ rifabutin active metabolites, ↓ EVG               |
|                    | RAL    | ↑ RAL                                               |
| Rifampin            | BIC    | ↓ BIC                                               |
|                    | CAB    | ↓ CAB                                               |
|                    | DTG    | ↓ DTG                                               |
|                    | EVG/c  | ↓ EVG & COBI                                        |
|                    | RAL    | ↓ RAL                                               |
| Rifapentine         | BIC    | ↓ BIC                                               |
|                    | CAB    | ↓ CAB                                               |
|                    | DTG    | ↓ DTG                                               |
|                    | EVG/c  | ↓ EVG & COBI                                        |
|                    | RAL    | ↑ or ↓ RAL                                          |
| **Cardiac medications** | | |
| Amiodarone          | EVG/c  | ↑ amiodarone                                        |
| Beta-blockers (i.e., metoprolol, timolol, etc.) | EVG/c  | ↑ beta-blockers                                    |
| Calcium channel blockers (CCBs) | EVG/c  | ↑ CCB                                               |
| Dofetilide          | BIC, DTG | ↑ dofetilide                                      |
| Eplerenone          | EVG/c  | ↑ eplerenone                                        |
| **Herbal products** |        |                                                     |
| St. John’s Wort     | BIC, CAB, DTG | ↓ BIC & DTG                                    |
|                    | EVG/c  | ↓ EVG & COBI                                        |
susceptibility to EVG [65–69]. E92Q is the most common initial mutation that is seen with failure on EVG-based regimens, followed by N155H and Q148H/R/K [70]. In the presence of E92Q, high-level resistance is conferred to EVG and intermediate-level resistance is conferred to RAL [71]. For individuals with EVG or RAL mutations, some of these INSTI mutations can be overcome by using twice daily dosing of DTG rather than its standard once daily dosing in combination with an optimized background regimen [40].

For second generation INSTIs, amino acid substitutions E92Q, G118R, S153F/Y, G193E, R263K decrease

| Coadministered Drug | INSTI | Effect on INSTI or Coadministered Drug Concentrations |
|---------------------|-------|-----------------------------------------------------|
| **Hormonal therapies** |       |                                                     |
| Contraceptives: non-oral | BIC, CAB, DTG, RAL | Etonogestrel (subdermal implant) † with DTG ↔ BIC, CAB, RAL |
| Contraceptives: oral | BIC, CAB, DTG, RAL | ↔ ethinyl estradiol, norgestimate, ↔ levonorgestrel with PO CAB |
| EVG/c | ↑ norgestimate, drospirenone |
| ↓ ethinyl estradiol |
| Gender-Affirming Therapy | EVG/c | ↑ estradiol, cyproterone, dutasteride, & finasteride ↑ testosterone |
| Menopausal Hormone Replacement Therapy | BIC, CAB, DTG, RAL | ↓ estrogen from conjugated estrogen (equine or synthetic) or estradiol ↔ drospirenone, medroxyprogesterone, or micronized progesterone |
| BIC, CAB, EVG/c | ↓ or ↑ estrogen, ↑ drospirenone, PO medroxyprogesterone, PO micronized progesterone |
| **Immunosuppressive drugs** |       |                                                     |
| Cyclosporine, everolimus, sirolimus, tacrolimus | EVG/c | ↑ immunosuppressive therapy |
| **Lipid-modifying agents** |       |                                                     |
| Atorvastatin | EVG/c | ↑ atorvastatin |
| Lomitapide | EVG/c | ↑ lomitapide |
| Lovastatin | EVG/c | ↑ lovastatin |
| Pitavastatin, pravastatin | EVG/c | No data |
| Rosuvastatin | EVG/c | ↑ rosuvastatin |
| Simvastatin | EVG/c | ↑ simvastatin |
| **Narcotics/ opioid dependence treatment** |       |                                                     |
| Buprenorphine (Sublingual, buccal, or implant) | EVG/c | ↑ buprenorphine, norbuprenorphine |
| RAL | ↔ sublingual, implant |
| Fentanyl | EVG/c | ↑ fentanyl |
| Lofexidine | EVG/c | ↑ lofexidine |
| Methadone | BIC, CAB, DTG, EVG/c, RAL | No significant effect |
| Tramadol | EVG/c | ↑ tramadol, ↓ M1 (active metabolite) |
| **PDE-5 inhibitors** |       |                                                     |
| Avanafil | EVG/c | No data |
| Sildenafil | EVG/c | ↑ sildenafil |
| Tadalafil | EVG/c | ↑ tadalafil |
| Vardenafil | EVG/c | ↑ vardenafil |
| **Sedatives/hypnotics** |       |                                                     |
| Alprazolam, clonazepam, clorazepate, diazepam, estazolam, flurazepam | EVG/c | ↑ benzodiazepines |
| Midazolam, triazolam | DTG | ↔ midazolam |
| EVG/c | ↑ midazolam, triazolam |
| Suvorexant | EVG/c | ↑ suvorexant |
| Zolpidem | EVG/c | ↑ zolpidem |

BIC bictegravir, CAB cabotegravir, COBI cobicistat, DTG dolutegravir, EVG/c elvitegravir/cobicistat, IM intramuscular, INSTI integrase strand transfer inhibitor, PO by mouth, RAL raltegravir [2, 10–12, 119, 120]
DTG susceptibility two- to four-fold [72]. M50I tends to be selected in vitro by DTG and BIC in combination with R263K, contributing to reduced DTG susceptibility [72]. The R263K, E92Q, Y143R, N155H, and Q148R substitutions confer 1.8-, 1.2-, 1.1-, 1.0- and 0.7-fold reduced susceptibility to BIC in vitro, respectively [73]. 

In clinical trials and in clinical practice, INSTI resistance is uncommon. One study evaluated integrase genotyping results of over 3,000 individuals between 2009 and 2012 and found that 15.6% of individuals had viruses with one or more integrase major mutations, most mutations being either N155H or Q148H/K/R [70]. Resources such as the HIV Stanford Database should be referred to frequently as interpretation of susceptibilities of these INSTIs to various polymorphisms may change as newer data become available [71, 74]. Refer to Table 3 for a list of major INSTI resistance associated mutations (RAMs) and how these affect the susceptibility of each INSTI. This table was created based on the Drug Resistance Mutation (DRM) penalty scoring system utilized by the HIV Stanford Database. The reader is encouraged to refer to the HIVdb program within the HIV Stanford Database for additional details regarding DRM penalty scoring [71].

Even with the structural improvements to second generation INSTIs, it is evident by their resistance profiles described above that these compounds are still susceptible to viral resistance. Recent studies have investigated utilization of red-capped mangabey simian immunodeficiency (SIV) integrases to better visualize the mode of INSTI binding within the intasome and thus better understand generation of INSTI resistance at this important site. Findings from such studies suggest that amino acid substitutions resulting in INSTI resistance are driven by extremely sensitive magnesium ion binding geometry within the active site, a phenomenon that the virus can manipulate for its own survival benefit [48, 75]. In this regard, the dependence of INSTIs on metal ion coordination is both their strength and weakness. Studies examining interactions between INSTIs and the HIV/SIV intasome propose that further extending the INSTI scaffolds into "free spaces" toward the integrase backbone in a manner that creates more contacts within the active site is a concept that should be explored to stabilize binding geometry and thus improve the ability of new INSTIs to overcome potential resistance [44, 48, 75]. A structural modification that has shown promise in retaining potency against known mutant variant combinations is the development of compounds containing various modifications of a naphthyridine core scaffold. In general, these compounds tend to bind closer to integrase in the active site, supporting their ability to avoid development of viral RAMs [45].

### Table 3 Relative Resistance of INSTI Resistance Associated Mutations (RAMs)

| RAMs      | INSTI | RAL | EVG | CAB | DTG | BIC |
|-----------|-------|-----|-----|-----|-----|-----|
| Y143R/C/H/S | ++++ | +   | +   | −   | −   | −   |
| S147G     | +    | ++++| +   | +   | +   | +   |
| E138K/A/T  | +    | +   | +   | +   | +   |
| G140S/A/C  | ++   | +++ | +   | +   |
| E92G/Q     | +++  | ++++| +   | +   |
| N155H     | ++++ | ++++| ++  | +   |
| F121Y     | ++++ | ++++| +   | +   |
| T66A/K     | ++++ | ++++| +   | +   |
| Q148H/R/K  | ++++ | ++++| ++++| +   |
| R263K     | +    | +++| +   | +   |
| G118R     | ++++ | ++++| ++++| +   |

* susceptible | + potential low-level resistance | ++ low-level resistance | ++ intermediate resistance | +++ high-level resistance

* Susceptible: no evidence of reduced ARV susceptibility compared with wild-type virus

* Potential low-level resistance: sequence may contain mutations indicating previous ARV exposure or many contain mutations that are associated with drug resistance only when they occur with additional mutations

* Low-level resistance: Virus encoded by specific sequence may have reduced in vitro ARV susceptibility, or patients harboring viruses with the submitted mutations may have a suboptimal virological response to treatment

* Intermediate resistance: High likelihood that drug’s activity will be reduced, but the drug will likely retain significant antiviral activity

* High-level resistance: predicted level of resistance is like those observed in viruses with the highest levels of in vitro drug resistance, or clinical data exist demonstrating patients typically have little or no virologic response to treatment with the ARV [71]

Resistance outside of integrase region Virologic failure to second generation INSTIs has occurred in patients who had no selected mutations in the integrase gene [76–78]. Such findings have suggested that HIV-1 can use alternative mechanisms to develop resistance to INSTIs outside of the integrase gene. One of the two more studied methods outside of integrase by which HIV-1 has developed resistance to INSTIs is by changes to the 3-prime polyurine tract (3’-PPT). The 3’-PPT is a primer required during the process of reverse transcription from HIV-1 RNA into double-stranded DNA. Malet et al. reported that following in vitro selection with high plasma concentrations of DTG, an HIV-1 strain showed no mutations in integrase, but multiple mutations in the 3’-PPT [79]. Wijting et al. reported similar findings in vivo with a patient failing dolutegravir maintenance monotherapy who developed mutations in the 3’-PPT and not in the integrase gene [80]. However, other studies suggest that mutations in the 3’-PPT in individuals failing INSTI treatment may not necessarily contribute to INSTI resistance [81]. Recent findings suggest there may be an explanation...
for resistance to INSTIs in this setting; through further in-vitro investigation of the mutations in 3'-PPT noted by Malet et al., DTG did not impair the replication of these mutants and no integrated viral DNA could be detected. Instead, accumulation of unintegrated viral DNA was observed [82]. Previous studies have shown that unintegrated viral DNA is involved in the expression of some early viral proteins and under certain conditions, unintegrated viral DNA has led to low-level viral replication [83, 84]. These findings highlight the important role of unintegrated viral DNA in overall viral replication in patients treated with INSTIs and may help explain why some patients experience INSTI treatment failure while failing to develop integrase RAMs. Additional studies are warranted to better understand the mechanism by which mutations in the 3'-PPT may play a role in causing resistance to second generation INSTIs.

The second means by which INSTI resistance has been observed outside of the integrase gene is via mutations in the HIV-1 envelope glycoprotein complex (env). To describe this method of resistance acquisition, it is useful to first understand the role of env in productive viral transmission. Infectious particles that can lead to spread of infection are generated from the expression of env on membranes of both free virions and infected cells [85]. Two glycoprotein (gp) subunits of env are gp120 and gp41. Once gp120 binds to CD4 on the target cell surface, a conformational change is triggered in env, exposing the chemokine coreceptor (CCR5 or CXCR4)-binding site which allows for gp41-mediated fusion of the viral and host cell membranes [86]. Viral transmission from infected to uninfected cells can occur via two methods: cell-free infection or cell–cell transmission at points of cell–cell contact known as virological synapses. The virological synapses are formed by the interaction of env of the infected cell with the CD4 receptor on the target cell [86, 87]. Transmission occurring via the cell–cell route is significantly more effective than cell-free infection, leading to a higher multiplicity of infection (MOI) and thus a greater likelihood of overcoming ARV activity, among other barriers to infection [88].

In recent studies, investigation into treatment failure with INSTIs without emergence of INSTI RAMs has led to discoveries of mutations to the env-coding region [85, 89]. These env mutations appear to allow for an even greater efficiency of transmission between cells and suggest that it is possible for HIV-1 to avoid inhibitory activity of all ARVs via mutations in env. Interestingly, Van Duyne and colleagues observed that the calculated fold-change for certain env mutations is comparable to multiple integrase mutants in patients experiencing virologic failure with DTG [74, 85]. Like other mechanisms outside of integrase that confer resistance to INSTIs, further research is needed to elucidate the role of this mechanism of drug resistance and the impact of env mutations on the effectiveness of ARVs.

### Clinical studies involving efficacy and safety and tolerability of INSTIs in treatment-naive individuals living with HIV

A summary of the clinical efficacy and safety of first generation INSTIs RAL and EVG at week 48 can be found in Tables 4 and 5, respectively, for convenience of viewing and comparing to second generation INSTIs. For the purposes of this review, second generation INSTIs will be discussed in more detail below.

#### Dolutegravir clinical efficacy

The clinical efficacy and safety of DTG were evaluated in three landmark phase 3 randomized, double-blind, active-controlled trials [6, 92, 93]. Refer to Table 6 for a summary of virologic efficacy data of all three trials at week 48. The first trial, SPRING-2, was the first head-to-head comparison of two INSTI-based regimens for first-line ART, comparing once daily DTG versus twice daily RAL in treatment-naive individuals [92]. By week 48 of the 20 individuals (5%) in the DTG group and 28 (7%) in the RAL group that had protocol-defined virologic failure (PDVF), no individuals in the DTG group and one in the RAL group developed INSTI resistance. By week 96, 81% of individuals in the DTG treatment group and 76% in the RAL treatment group had HIV-1 RNA < 50 copies/mL [6]. Through follow-up at week 96, two additional individuals in the DTG group and one in the RAL group developed PDVF; however, no additional INSTI resistance was detected in either treatment group [6, 92].

The second trial, SINGLE, compared the efficacy of DTG with either ABC/3TC or FTC/TDF to efavirenz (EFV)/FTC/TDF in treatment-naive individuals [93]. By week 48, of the 18 (4%) individuals in the DTG group that met criteria for PDVF (defined as two consecutive HIV-1 RNA values of > 50 copies/mL on or after week 24) and had resistance testing performed, only two had more than low-level viremia (HIV-1 RNA of > 200 copies/mL), with no integrase RAMs detected [93]. Week 96 results showed 80% of individuals in the DTG group and 72% in the EFV group had HIV-1 RNA < 50 copies/mL [8]. Through week 144, 71% of individuals in the DTG group and 63% in the EFV group achieved virologic suppression of HIV-1 RNA < 50 copies/mL [8]. Through week 144, among 39 (9%) of individuals who met criteria for PDVF, 29 of these had low-level viremia with no integrase RAMs detected in the DTG group [94].

The third trial, GEMINI-1 and GEMINI-2 were duplicate non-inferiority studies in treatment-naive adult individuals infected with HIV-1 comparing the
Table 4  First Generation INSTIs: Virologic Outcomes at Week 48 (FDA Snapshot)

|                  | STARTMRK | ONCEMRK | GS-US-236–0102 | GS-US-236–0103 | GS-US-292–0104/0111 |
|------------------|----------|---------|----------------|----------------|---------------------|
|                  | RAL + FTC/ TDF | EFV + FTC/ TDF | RAL 1200 QD + FTC/ FTC | RAL 400 BID + FTC/ FTC | EVG/ COBI/ FTC/ TDF |
| HIV-1 RNA < 50 copies/mL | n = 281 | n = 282 | n = 531 | n = 266 | n = 348 |
|                  | 241 (86.1%) | 230 (81.9%) | 472 (89%) | 235 (88%) | 305 (87.6%) |
| Difference, % (95% CI) | 4.2 (−1.9, 10.3) | −0.5 (−4.2, 5.2) | 3.6 (−1.6, 8.8) | 3.0 (−1.9, 7.8) | 2.0 (−0.7, 4.7) |
| HIV-1 RNA ≥ 50 copies/mL | 27 (9.6%) | 39 (13.8%) | 29 (5%) | 16 (6%) | 25 (7.2%) |
| No virologic data | – | – | 30 (6%) | 15 (6%) | 18 (5.2%) |
| INSTI resistance mutations detected | E92Q + L74L/M + T97T/A + Y143Y/H | None | E92Q + L74M | None | E92Q, N155H; Q148R, T66I |
| References | [30] | [63] | [91] | [11] | [65] |

Dash (-) indicates that information was not reported in the study results.

3TC lamivudine, ABC abacavir, ATV atazanavir, BIC bictegravir, CI confidence interval, COBI cobicistat, DTG dolutegravir, EFV efavirenz, EVG elvitegravir, FDA food and drug administration, FTC emtricitabine, INSTI integrase strand transfer inhibitor, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate, NRTI nucleoside reverse transcriptase inhibitor, RAL raltegravir, RTV ritonavir.

HIV-1 RNA reported as HIV-1 RNA < 40 copies/mL

HIV-1 RNA < 40 copies/mL

HIV-1 RNA ≥ 50 copies/mL
| Adverse Reaction               | Raltegravir (RAL + FTC/TDF) | Elvitegravir (EVG/COBI/FTC/TDF) |
|-------------------------------|-----------------------------|---------------------------------|
|                               | START.MRK<sup>a</sup>       | ONCE.MRK<sup>a</sup>            | GS-236-0102<sup>b</sup> | GS-236-0103<sup>b</sup> | GS-292-0104/0111<sup>d</sup> |
| Diarrhea                      | RAL n = 281                 | EFV n = 282                     | EVG/ COBI/ FTC/ TDF n = 348 | EFV/ FTC/ TDF n = 352 | EVG/ COBI/ FTC/ TDF n = 353 | ATV/ RTV + FTC/ TDF n = 355 | EVG/ COBI/ FTC/ TAF N = 866 | EVG/ COBI/ FTC/ TDF N = 867 |
| Nausea                        | 1%                          | 3%                              | 2%                           | 3%                      | 23%                        | 19%                        | 22%                        | 27%                        | 17%                        | 19%                        |
| Vomiting                      | -                           | -                               | -                            | -                       | -                          | -                           | -                           | -                           | -                           | -                           |
| Fatigue                       | 1%                          | 3%                              | -                            | -                       | 11%                        | 13%                        | 14%                        | 13%                        | 8%                          | 8%                          |
| Upper respiratory infection   | -                           | -                               | -                            | -                       | 14%                        | 11%                        | 15%                        | 16%                        | 11%                        | 13%                        |
| Dizziness                     | 1%                          | 6%                              | 2%                           | 3%                      | 7%                         | 24%                        | -                          | -                          | -                           | 5%                          | 4%                          |
| Headache                      | 4%                          | 5%                              | 3%                           | 5%                      | 14%                        | 10%                        | 15%                        | 12%                        | 14%                        | 13%                        |
| Insomnia                      | 4%                          | 3%                              | -                            | -                       | 9%                         | 14%                        | -                          | -                          | -                           | 7%                          | 6%                          |
| Depression                    | -                           | -                               | -                            | -                       | 9%                         | 11%                        | -                          | -                          | -                           | -                           | -                           |
| Rash                          | -                           | -                               | -                            | -                       | 6%                         | 12%                        | -                          | -                          | -                           | 6%                          | 5%                          |
| Discontinuations due to drug-related clinical adverse events | 1%                          | 4%                              | 0%                           | 1%                      | 4%<sup>c</sup>            | 5%<sup>c</sup>            | 4%<sup>c</sup>            | 5%<sup>c</sup>            | 1%                          | 1%                          |

References: [90] [63] [91] [11] [65]

Dash (-) indicates that information regarding this adverse effect was not reported in the study results.

ATV/atazanavir, COBI/cobicistat, EFV/efavirenz, EVG/elvitegravir, FTC/emtricitabine, RAL/raltegravir, RTV/ritonavir, TDF/tenofovir disoproxil fumarate

<sup>a</sup> Reported as drug-related clinical adverse events of moderate-severe intensity

<sup>b</sup> Reported as adverse events in ≥ 10% of patients in either group

<sup>c</sup> Discontinuations reported as patients with any treatment-emergent adverse event leading to premature discontinuation of study drug; whether they were deemed to be drug-related was not distinguished

<sup>d</sup> Reported as adverse events in ≥ 5% of patients in either group
## Table 6  Second Generation INSTIs: Virologic Outcomes at Week 48 (FDA Snapshot)

|                  | SPRING-2 | SINGLE | GEMINI-1 and -2 | GS-US-380–1489 | GS-US-380–1490 | FLAIR | ATLAS |
|------------------|-----------|---------|----------------|----------------|----------------|-------|-------|
|                  | DTG + 2 NRTIs, n = 411 | RAL + 2 NRTIs, n = 411 | DTG + ABC/3TC, n = 414 | EFV/FTC/TDF, n = 419 | DTG/3TC, n = 716 | DTG + FTC/TDF, n = 717 | BIC/FTC/TAF, n = 315 | DTG + FTC/TAF, n = 325 | BIC/FTC/TAF, n = 314 | BIC/FTC/TAF, n = 320 | CAB, n = 283 | CAR, n = 283 | CAB, n = 308 | CAR, n = 308 |
| HIV-1 RNA < 50 copies/mL | 361 (8.8%) | 351 (85%) | 364 (8.8%) | 338 (81%) | 655 (91%) | 669 (93%) | 293 (93%) | 290 (92%) | 302 (93%) | 286 (89%) | 265 (94%) | 264 (93%) | 285 (93%) | 294 (95%) |
| Difference, % (95% CI) | 2.5 (−2.2, 7.1) | 7.4 (2.5, 12.3; P = 0.003) | −1.7 (−4.4, 1.1) | −0.6 (−4.8, 3.6; P = 0.78) | −3.5 (−7.9, 1; P = 0.12) | −0.4 (−2.8, 2.1) | 0.7 (−1.2, 2.5) |
| HIV-1 RNA ≥ 50 copies/mL | 8 (2%) | 5 (1%) | 6 (1%) | 5 (1%) | 8 (2.5%) | 3 (1%) | 4 (1%) | 14 (4%) | 6 (2%) | 7 (2%) | 5 (2%) | 3 (1%) |
| No virologic data | 30 (7%) | 29 (7%) | 29 (7%) | 29 (7%) | 55 (13%) | 41 (6%) | 35 (5%) | 14 (4%) | 21 (7%) | 19 (6%) | 20 (6%) | 12 (4%) | 12 (4%) | 18 (6%) | 11 (4%) |
| INSTI Resistance Mutations Detected | None | T977A, E138D, V117I, N155H | None | None | None | None | None | None | None | None | None | Q41R, G140R | None | N155H, N155H + R263K | None |
| Reference | [92] | [93] | [96] | [97] | [98] | [99] | [100] |

Dash (-) indicates that information was not reported in the study results

3TC lamivudine, ABC abacavir, ATV atazanavir, BIC bictegravir, CAR raltegravir, COBI cobicistat; DTG dolutegravir, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, NRTI nucleoside reverse transcriptase inhibitor, RTV ritonavir, RAL raltegravir, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate
two-drug (2DR) regimen DTG plus FTC to the three-drug regimen (3DR) of DTG plus FTC/TAF. By week 48, 10 (<1%) individuals met criteria for confirmed virologic failure (six in the 2DR group and four in the 3DR group) with all these individuals discontinuing the study. No treatment-emergent resistance to any component was reported in either treatment group in both clinical trials. At week 96, 86% and 90% of individuals maintained virologic suppression in the treatment groups, respectively [95]. Furthermore, through week 144, 82% and 84% of individuals maintained virologic suppression, respectively [96]. Through week 144, a total of 12 individuals (1.7%) in the 2DR group and 9 (1.3%) in the 3DR group met criteria for confirmed virologic withdrawal. Of these, none had treatment emergent INSTI RAMs. One patient in the 2DR group did not meet confirmed virologic withdrawal study criteria but developed R263R/K integrase mutation and had an HIV-1 RNA of 135 copies/mL at week 144. This patient was later resuppressed with a protease-inhibitor and INSTI-based regimen [96].

**Dolutegravir safety and tolerability**

Refer to Table 7 for a summary of virologic safety data of all three trials at week 48. In SPRING-2 study, rates of adverse events leading to discontinuation were low. Increases in serum creatinine were observed in both treatment groups by week two and stabilized thereafter, and none of these cases resulted in treatment discontinuation. Rates of adverse events continued to be similar through week 96 with no additional subjects discontinuing treatment with DTG due to adverse events [76].

In the SINGLE trial, primary reasons for discontinuation of DTG were psychiatric disorder (n=2) and skin and subcutaneous-tissue disorder (n=2). Similar to the SPRING-2 trial, small increases in serum creatinine of 0.12 to 0.15 mg/dL were observed in DTG group by week two, stabilizing through week 48 [92, 93]. Tolerability and safety of both treatment groups continued to be similar through week 144. No clinically significant differences in abnormal laboratory parameters were observed between weeks 48 and 144 [94].

In the GEMINI-1 and -2 trials, reasons for discontinuation were not described. Changes in renal biomarkers and most of the bone turnover biomarkers significantly favored the 2DR, with mean change in these biomarkers from baseline significantly greater in the 3DR. At week 48, HDL increased significantly in the 2DR compared to the 3DR. These changes in lipid parameters are considered consistent with the anticipated effect of TDF on lipids [101]. Through week 144, the main reasons for discontinuation were psychiatric disorders (n=11 [2DR], n=8 [3DR]), renal related (n=2 [2DR], n=12 [3DR]), and osteoporosis (none in 2DR and two in 3DR).

Tolerability and safety observed in both treatment groups continued similarly through week 144, with comparable rates of adverse events of all grades across both treatment groups [96]. Of note, weight gain was noted in the study results of this trial and was observed in 2% of individuals per group; this led to discontinuation in one patient in the 2DR. The mean change in weight from baseline to week 144 was 3.7 kg in the 2DR and 2.4 kg in the 3DR. Through week 144, changes in renal biomarkers continued to favor the 2DR group, increases in bone turnover from baseline continued to be lower for the 2DR group, and lipid parameters generally favored the 3DR, which was consistent with the 48 week findings.

**Bictegravir clinical efficacy**

The clinical efficacy and safety of a FDC of BIC/FTC/TAF versus a DTG-based, 3-drug regimen in treatment-naïve individuals were assessed in two landmark phase 3 randomized, double-blind, active-controlled trials [97, 98]. Refer to Table 6 for a summary of virologic efficacy data of both trials at week 48. In the GS-1489 clinical trial, the efficacy of the FDC of BIC/FTC/TAF compared to the FDC of DTG/ABC/3TC as initial treatment of HIV-1 was evaluated [97]. The durability of the 48-week results was observed through week 96 (88% versus 90%) and week 144 (82% versus 84%) in both treatment groups, respectively [97, 102]. By week 48, one (<1%) patient in the BIC group and four (1.3%) in the DTG group met protocol-defined criteria for resistance testing. Of these, none had treatment emergent resistance.

The second trial, GS-1490, evaluated the efficacy of BIC/FTC/TAF compared to DTG plus FTC/TAF as initial treatment of HIV-1 infection [98]. By week 48, seven (2.1%) individuals in the BIC group and five (1.5%) in the DTG group met criteria for resistance testing, however no treatment resistance to any component of either regimen was observed [98]. Through week 144 as a composite analysis of both studies 1489 and 1490, a total of six (2%) individuals in the DTG group and none in the BIC group met criteria for resistance testing; no resistance was seen to any component of either treatment group [102].

**Bictegravir safety and tolerability**

Refer to Table 7 for a summary of virologic safety data of both trials at week 48. In the GS-1489 study, reasons for discontinuation of DTG/ABC/3TC were nausea and generalized rash (n=1), thrombocytopenia (n=1), chronic pancreatitis and steatorrhea (n=1), and depression (n=1). Grade 3 or 4 laboratory abnormalities were reported in 15% of individuals in both arms and were similar across each group. At week 144, adverse events
Table 7  Second Generation INSTIs: Selected drug-related adverse events after week 48 recorded in ≥ 2% or more patients in either treatment group

| Adverse reaction | Dolutegravir SPRING-2a | Bictegravir GS-US-380–1489a | Bictegravir GS-US-380–1490a | Cabotegravir FLAIR and ATLAS – Pooled Analysis |
|------------------|------------------------|------------------------|------------------------|----------------------------------|
|                  | DTG n = 411 RAL n = 411 | DTG n = 414 EFV n = 419 | DTG/3TC n = 716 | DTG and FTC/ TDF n = 717 |
| Diarrhea          | 11%                    | 11%                    | 17%                    | 18% |
| Nausea            | 14%                    | 13%                    | 14%                    | 4% |
| Vomiting          | –                      | –                      | –                      | – |
| Fatigue           | 5%                     | 4%                     | 13%                    | 12% |
| Upper respiratory infection | 6%          | 9%                     | 10%                    | 8% |
| Dizziness         | 6%                     | 6%                     | 9%                     | 35% |
| Headache          | 12%                    | 12%                    | 13%                    | 13% |
| Insomnia          | 5%                     | 4%                     | 15%                    | 10% |
| Depression        | 5%                     | 3%                     | 6%                     | 6% |
| Rash              | –                      | –                      | –                      | – |
| Pyrexia           | –                      | –                      | –                      | – |
| Injection site reactions | –            | –                      | –                      | – |
| Discontinuations due to drug-related clinical adverse events | 2% | 2% | 10% | 1% |

References [92] [93] [96] [97] [98] [99, 100]

Dash (-) indicates that information regarding this adverse effect was not reported in the study results or was reported as < 2% for both groups.

3TC lamivudine, BIC bictegravir, CAB cabotegravir, CAR current antiretroviral regimen, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, RAL raltegravir, RPV rilpivirine, TDF tenofovir disoproxil fumarate

a Adverse events reported as adverse events with ≥ 5% incidence in either group.
b Adverse events reported as adverse events with ≥ 4% incidence in either group.
and laboratory abnormalities were similar between both treatment groups [102].

In the GS-1490 study, the three discontinuations in the BIC group deemed related to the study drug at week 48 were due to chest pain (n = 1), abdominal distension (n = 1), sleep disorder, dyspepsia, tension headache, depressed mood, and insomnia (n = 1). The discontinuation in the DTG group was considered unrelated to the study drug [98]. Grade 3 or 4 laboratory abnormalities were reported in 17% of individuals in the BIC group and 13% of individuals in the DTG group; trends in these abnormalities were not observed across either group. At week 144, adverse events leading to discontinuation were reported similarly in both groups with six individuals (2%) in each [102].

**Cabotegravir clinical efficacy**

The clinical efficacy and safety of CAB were evaluated in two landmark phase 3 randomized, double-blind, active-controlled trials [99, 100]. Refer to Table 6 for a summary of virologic efficacy data of both trials at week 48. Because of CAB’s unique long-acting (LA) formulation, the study design for these comparison trials is different from its counterparts in the INSTI class; therefore, additional details have been included below.

The first trial, FLAIR, was a phase 3 randomized, open-label, non-inferiority trial designed for individuals naïve to HIV treatment. The trial included three main phases: induction, maintenance, and extension. The induction phase consisted of daily oral DTG/ABC/3TC for 20 weeks to reach virologic suppression, at which point individuals were randomized 1:1 to start maintenance phases of either oral lead-in therapy of the study drugs or continue oral therapy of DTG/ABC/3TC. Oral lead-in therapy consisted of CAB 30 mg and RPV 25 mg once daily for approximately four weeks before initiating a loading dose of LA CAB 600 mg (3 mL) and RPV 900 mg (3 mL) IM, followed by monthly IM injections of CAB 400 mg (2 mL) and RPV 600 mg (2 mL), with the maintenance phase designed to last for 96 weeks. The extension phase was offered to participants in the oral-therapy group who maintained viral suppression through week 96, which meant they could switch to long-acting therapy at this time [99].

Results from the study notably showed that at week 48, 91% of study participants preferred LA therapy [99]. By week 48, four participants in the long-acting therapy group had confirmed virologic failure with three cases developing NNRTI and INSTI RAMs during treatment. These participants all had L74I integrase mutation at baseline; however, 51 of the 54 individuals in the long-acting group who had this mutation at baseline did not have subsequent virologic failure. Through week 96, results remained consistent with no individuals developing virologic failure between week 48 and 96 [103].

The second trial, ATLAS, was a phase 3, open-label, multicenter noninferiority trial in which individuals who had plasma HIV-1 RNA levels of < 50 copies/mL for at least six months while taking a standard oral ARV regimen were either continued on their current regimen or switched to monthly IM injections of LA CAB and RPV [100]. After week 48, eligible participants could transition to the ATLAS-2 M study (investigating the same LA therapy but dosed every 8 weeks versus LA therapy dosed every 4 weeks) or enter the extension phase of ATLAS at week 52. In the extension phase, individuals either continued their LA every 4 weeks therapy or those who were originally randomized to their current ARV regimen were switched from that regimen to LA therapy every four weeks, this group being designated as the switch population [104].

Results from ATLAS at week 48 resulted in noninferiority criteria of the LA injectable being met. Of the individuals in the LA therapy group, three had confirmed virologic failure with no INSTI RAMs detected. Of note, there were no missed injections or late-administered injections for any patient experiencing virologic failure [100]. Of the participants who remained in the trial via the extension phase (through week 96), 100% (n = 23) of individuals originally in the LA group and 97% (n = 28/29) of individuals in the switch population maintained virologic suppression. Although no participant in either group met confirmed virologic failure criteria, one patient with HIV-1 RNA > 50 copies/mL at week 96 was placed on a protease-inhibitor based regimen for continued follow-up [104].

**Cabotegravir safety and tolerability**

Refer to Table 7 for a summary of virologic safety data of both trials at week 48. In the combined FLAIR and ATLAS pooled analyses, the primary reason for withdrawal, although minimal, was injection-site reactions (1%). Other reasons for withdrawal from treatment (incidence < 1%) were viral hepatitis, diarrhea, and headache. The median weight gain from baseline was 1.3 kg by week 48 in the long-acting therapy group compared to 1.0 kg in the comparator group. Grade 3 or 4 laboratory abnormalities observed most in the long-acting group were elevations in creatine kinase (9%), direct bilirubin (5%), and lipase (6%).

Through week 96 in the FLAIR study, discontinuations due to adverse events increased to 14 individuals (5%) in the long-acting group, with five of these considered drug-related. Reasons for withdrawal from treatment for these individuals were similar to the 48-week findings. Five additional individuals in the long-acting group
discontinued treatment between 48 and week 96 for reasons such as depression, viral hepatitis, and injection site pain. By week 96, the median weight gain was 2.0 kg in both the long-acting group and similarly in the standard care group. The most commonly observed laboratory abnormalities in the long-acting group did not differ from week 48 results [103].

Clinical studies involving efficacy and safety and tolerability of cabotegravir for pre-exposure prophylaxis of HIV

Clinical efficacy
The clinical efficacy and safety of LA CAB as PrEP of HIV-infection has been evaluated in two phase 3 randomized, double-blind, multicenter international studies, HPTN-083 and HPTN-084, and the nature of these studies are described below [105, 106].

Both HPTN-083 and HPTN-084 trials included the same three phases: oral-tablet lead-in phase, an injection phase, and a “tail phase.” In both treatment groups, all participants were given an oral daily active study drug, either of CAB or FTC/TDF as a fixed dose, for up to five weeks to demonstrate patient tolerability. To initiate the injection phase, all participants were given 3-ml IM injections at months 1 and 2, then every eight weeks thereafter for a period of 153 weeks along with a placebo (either injection or oral tablet) of the alternative treatment. The tail phase included monitoring beginning eight weeks after the final injection and continuing for approximately 48 weeks [105, 106].

The first trial, HPTN-083, was designed for cisgender men and transgender women (TGW) who have sex with men. Results from the study showed that at week 153, 12 (0.37%) participants in the CAB group versus 39 (1.22%) participants in the FTC/TDF group had acquired incident HIV-1 infection (hazard ratio 0.31 [95% CI 0.16–0.58]). The low incidence rate in both arms demonstrated that both study drug agents were effective in preventing HIV. Of the 12 individuals that developed incident infection, INSTI RAMs were detected in 4 participants and included the following: E138A, E138E/K, E157Q, G140A, G140G/S, L74I, Q148R, and R263K. Results from the study suggest that CAB LA yielded a 69% lower risk in acquiring HIV infection among cisgender men and TGW who have sex with men compared to FTC/TDF, meeting the superiority criteria of long acting CAB (P = 0.0003) [105].

The second trial, HPTN-084 was designed for cisgender women at risk for HIV infection. Results from the study showed that at week 153, 4 (0.2%) participants in the CAB group versus 36 (1.85%) participants in the FTC/TDF group had acquired incident HIV-1 infection (hazard ratio 0.12 [95% CI 0.05–0.31]). Poor medication adherence was demonstrated when 98% (n = 35) participants in the FTC/TDF group had inadequate tenofovir and tenofovir diphosphate concentration at the time of HIV infection [106]. Of the 36 individuals who acquired HIV infection in the FTC/TDF group, only 1 participant had NRTI mutations with the primary resistance mutation being M184V. No major integrase RAMs were detected in any of the four HIV infections observed in the CAB group. By week 153, results from the study suggest that cisgender women in the CAB LA group had an 88% lower risk in acquiring HIV infection compared to those in the FTC/TDF group, thus, meeting superiority criteria of long acting CAB [106].

Safety and tolerability
In the HPTN-083 study, Grade 3 or higher laboratory abnormalities were reported in 31.9% of participants in the CAB group and 33.6% of participants in the FTC/TDF group. The most common laboratory abnormalities were increased creatinine, decreased creatinine clearance, increased serum creatinine, increased lipase, increased aspartate aminotransferase (AST), and increased alanine aminotransferase (ALT). Discontinuation because of a clinical adverse event occurred in 6% individuals in the CAB group and 4% individuals in the FTC/TDF group. Injection site-related adverse events leading to discontinuation occurred in 2.4% (n = 50) participants in the long-acting CAB group. Mean changes in weight gain from baseline differed between the treatment groups with a greater increase occurring in the CAB group (1.23 kg) versus the FTC/TDF group (0.37 kg) [105].

In the HPTN-084 study, discontinuation because of a clinical adverse event occurred in 1% in the CAB group and 1% in the FTC/TDF group. Adverse events leading to discontinuation occurred in two individuals in the CAB group due to hospitalization for fetal distress and respiratory tract infection. Grade 3 or higher laboratory abnormalities were reported in 17.1% of participants in the CAB group and 17.4% of participants in the FTC/TDF group. The most common laboratory abnormalities were decreased creatinine clearance, increased creatinine, increased creatine kinase, abnormal weight loss, increased ALT, and increased AST. Mean changes in weight gain from baseline did not differ significantly between treatment groups with an increase of 2.4 kg in the CAB group compared to 2.1 kg in the FTC/TDF group [106].

Clinical considerations
INSTIs used for treatment-naïve individuals living with HIV have shown excellent rates of virologic suppression at week 48 ranging from 85 to 93%, in addition to
favorable tolerability versus other ARV class comparator groups. Furthermore, the efficacy of these INSTIs have been sustained with extended duration of use [67, 69, 76, 107]. Taken together, all these studies support the recommended use of INSTIs for first line treatment of individuals living with HIV. Refer to Fig. 2 for a summary of additional relevant clinical considerations for helping clinicians choose between the various INSTIs used for treatment of people living with HIV.

**Resistance**

One of the major advantages of starting treatment in individuals living with HIV with second generation INSTIs like DTG or BIC is their characteristically high genetic barrier to resistance compared to the first generation INSTIs, RAL and EVG, and other ARV classes such as NNRTIs (for example: EFV and RPV) [49, 73, 108, 109]. The high genetic barrier to development of resistance of DTG, BIC, and to a lesser extent CAB may be attributed to their slower dissociation half-lives, making them advantageous over RAL and EVG in the presence of INSTI RAMs. Reports of INSTI RAMs were detected in clinical studies involving RAL and EVG (refer to Table 4). However, negligible treatment-emergent resistance to BIC and DTG were reported in treatment-naive individuals in clinical studies, further supporting their durable role as effective agents for treating HIV (refer to Table 6) [92, 93, 98, 110–112]. Current evidence also supports switching INSTIs from DTG to BIC with either FTC/TDF or FTC/TAF even in the presence of pre-existing
NRTI resistance, further illustrating BIC’s high genetic barrier to resistance [113]. For this reason and given that transmission rates of resistance are low among INSTIs, the use of second generation INSTI containing regimens including DTG or BIC are preferred as viable options in individuals needing to initiate rapid start for treatment of HIV [2]. Additionally, although rates of treatment failure with second generation INSTIs are low, further study of resistance pathways outside of the integrase gene will lead to a greater understanding of these mechanisms and potential solutions to overcoming associated resistance.

**Safety/adverse effects**

Overall, the most common adverse effects associated with INSTIs in clinical studies were diarrhea, nausea, insomnia, fatigue, and headache. Reported adverse events leading to discontinuation tended to be lowest in clinical studies involving BIC and DTG (< 2%) and slightly higher for RAL and EVG groups (< 1% to 4%). Furthermore, there were significantly fewer discontinuations secondary to adverse events for those individuals treated with the INSTI EVG versus comparator arms including EFV and ATV/r, as well as with DTG versus EFV [11, 91, 93]. These findings account for one of the primary reasons why the use of INSTIs is preferred as recommended first-line choices over other drug classes such as NNRTIs and PIs.

Discontinuations of treatment due to renal adverse events mostly occurred in individuals who were receiving EVG/COBI/FTC/TDF [11, 91]. No discontinuations due to renal adverse events occurred in the EVG/COBI/FTC/TAF treatment group, thus, supporting greater tolerability of TAF versus TDF related to renal safety. Fewer renal and bone toxicities associated with TAF may be attributed to its mechanism of action. Although both TAF and TDF are oral prodrugs of TFV, TAF was developed with improved safety and efficacy compared to TDF. TAF is more stable in plasma and is metabolized inside target cells via hydrolysis by intracellular cathepsin A, which results in higher intracellular levels of the active metabolite TFV diphosphate and lower plasma levels of TFV [114, 115]. Clinical studies using TAF have shown smaller changes in creatinine clearance and less tubular proteinuria as compared to those receiving TDF with the same background ART regimen [65, 115, 116]. However, some disadvantages of TAF include worsening effects on lipids and cumulative weight gain relative to TDF [117]. Compared to TDF, which has been shown to have lipid-suppressing benefits, increases in TG and simultaneous increase in LDL and HDL cholesterol have been observed in individuals switching from TDF to TAF [118]. For these reasons, it is understandable that fixed-dose combination INSTIs are moving toward inclusion of TAF over TDF.

Small incremental changes in renal parameters were observed initially in the first few weeks after starting treatment with EVG/COBI and stabilized thereafter with extended treatment. These effects of COBI on serum creatinine and mean estimated glomerular filtration rate (eGFR, Cockcroft-Gault, mL/min) are also consistent with results from studies evaluating protease inhibitors ATV and darunavir for the treatment of HIV, further supporting the effects of COBI on tubular secretion of serum creatinine [119–123]. COBI has been associated with small increases in serum creatinine and corresponding decreases in eGFR because of its effects on tubular secretion rather than glomerular filtration of serum creatinine [10]. In vitro data have demonstrated that COBI is a weak inhibitor of human renal transporters OCT2 and MATE2-K and is a more potent inhibitor of OCTN1 and MATE1 [10]. DTG and BIC are also known to be inhibitors of renal transporters OCT2 and MATE1. Since creatinine is a substrate of MATE1, inhibition of MATE1 by COBI, DTG and BIC may provide a plausible biological explanation for the small increases in serum creatinine and slightly reduced eGFR observed in clinical studies [8, 66, 76, 97, 98]. The magnitude of these changes in eGFR is not considered to be clinically significant, since they are relatively small and did not progress with extended treatment.

Weight gain has also been observed after the initiation of INSTI-containing regimens in ART naive individuals. BIC and DTG are associated with the largest weight gain from baseline, and generally INSTIs are associated with greater weight gain than with either NNRTIs or boosted PIs [102, 124]. The mechanism by which this weight gain occurs is not fully understood. Some studies have shown an association between ARV-related weight gain and/or body mass index changes and certain populations such as women and Black and Hispanic populations. However, further study is warranted to understand both of what predictors, if any, exist for this phenomenon, as well as the cardiovascular and metabolic implications associated with weight gain [13, 125–130].

INSTIs may exacerbate psychiatric symptoms but occur with low frequency compared to ARVs such as EFV and they rarely necessitate discontinuation [131, 132]. Although central nervous system-related adverse events such as headache, insomnia, dizziness, and depression occurred for some individuals in landmark clinical studies involving INSTIs, very few were severe enough to lead to discontinuation. It is difficult to fully grasp the impact of INSTIs on the development of neuropsychiatric events since documentation of these can vary depending on the
scales used and how they are reported. However, since depression is common in the HIV population, caution and close monitoring is recommended when starting treatment with any INSTI, especially, for those who have a history of depression and are receiving treatment with an antidepressant or other psychotropic medications.

Drug-gene interactions may also play a role in increasing the risk for adverse effects in individuals treated with DTG. One observational study including 107 Japanese patients with HIV-1 infection showed that those individuals who carried reduced function variants (*6 and *28) in UGT1A1 had higher median plasma DTG concentrations and were reported to have a significantly higher cumulative incidence of neuropsychiatric adverse events (defined as dizziness, headache, insomnia, restlessness, and anxiety) than those who carried normal alleles in UGT1A1. Although the severity of the neuropsychiatric adverse events was grade 1 or 2, six subjects discontinued DTG because of these adverse events. The impact of reduced function variants in UGT1A1 (i.e., poor metabolizer status) on incidence of adverse events and treatment outcomes associated with INSTIs warrants further study. This is especially important for those population groups, where some of these variants are commonly representative (30–40%) such as in European and African American populations, and also given that DTG is recommended as a first line treatment for most individuals with HIV worldwide [133].

Demographics and special populations

Most of the major clinical studies involving INSTIs included predominantly white populations, males, and mean age was in the 30s. One strength of the BIC clinical studies is the heterogeneity of the overall populations, including diverse ethnicities such as Black or African descent (30–36%) and Hispanic/Latino populations (21–26%) [97, 98]. Most of these studies also included those who had either HBV or hepatitis C virus (HCV) coinfection with comparable efficacy. Therefore, additional benefits of using EVG- or BIC-based FDCs include ability to treat HBV co-infection simultaneously. Together, this may collectively increase adherence to treating both HBV and HIV infections. It is worth noting that FDCs such as DTG/ABC/3TC, DTG/3TC and DTG plus RPV as well as the long acting CAB with RPV combination are not recommended for treatment of HBV co-infection since they do not include the standard two NRTIs recommended for treatment of HBV in patients living with HIV.

Another important demographic in these clinical studies was that the mean age was considerably young (mid-30s). Given that the HIV population is aging, additional clinical studies are warranted to determine the efficacy and safety of the use of INSTIs in elderly populations. Although this information is not fully known, one major advantage of INSTIs (especially, RAL, DTG, BIC and CAB) include fewer DDIs compared to EVG/CObi and other ARV classes such as PIs and NNRTIs. This is particularly critical in an aging HIV population with increased comorbidities and concomitant polypharmacy. Furthermore, the INSTIs RAL, DTG and BIC seem to have the least DDIs with direct acting antivirals compared to other ARV classes when treating common co-infections such as HCV [134]. With regards to another demographic variable such as gender, the INSTIs EVG and DTG demonstrated superior efficacy to their comparative groups including ATV/RTV-based regimens in treatment-naïve women living with HIV [135, 136].

In recent years, there has been increased interest in exploring potential associations between INSTIs and cardiovascular disease. An ongoing prospective, multicenter study including almost 30,000 people living with HIV examining INSTI exposure and the incidence of cardiovascular disease reported that after an average of six years of follow up, patients exposed to an INSTI experienced an increased cardiovascular risk within the first two years of INSTI exposure compared to those with no INSTI exposure. However, with continued follow-up, it was found that cardiovascular risk subsequently decreased to levels similar to those never exposed to an INSTI [137]. These findings merit further exploration into the possible relationship between INSTIs and cardiovascular disease, including attributable potential mechanisms responsible for this association and whether these risks vary by choice of INSTI.

Previously, DTG was recommended as an alternative ARV in individuals of childbearing potential who are trying to conceive or who are sexually active without using effective contraception. Reasoning for this limitation was based on a study in Botswana that showed that DTG exposure around the time of conception may be associated with an increased risk of infant neural tube defects [138]. Additional data from this same study have shown that this risk is considerably lower than original preliminary data suggested [139, 140]. Furthermore, given that these differences in rates were not significantly different to those with non-DTG containing regimens, DTG is now recommended as a preferred option for people of childbearing potential [141].

Other advantages of INSTIs include their use in other special populations such as children and acute HIV infection. One of the major advantages of RAL includes its availability in numerous various dosage formulations (especially, the chewable tablet formulation and oral suspension), which can help facilitate excellent adherence in young children living with HIV. Furthermore, RAL can also be used as early as birth. Recently in the United
States there have been many approvals of additional pediatric formulations such as: (1) a dispersible tablet for oral suspension for DTG for infants as young as 4-weeks old, (2) a low FDC of BIC/FTC/TAF for children weighing at least 14 kg, and (3) a low FDC of DTG/ABC/3TC for children weighing 10–25 kg [22, 142]. It is important to note, however, that the dosing between adult and pediatric formulations cannot be interchanged on a mg-to-mg basis due to their varying pharmacokinetic profiles, specifically with DTG.

The potency of INSTIs in clinical scenarios such as acute HIV infection and rapid start lends itself well in reducing HIV viral load very quickly compared to other ARV classes, which may reduce the size and development of latent viral reservoirs, thus limiting the overall impact of HIV disease progression and transmission [143]. It is worth noting that a more rapid viral load decline such as that seen with treatment of INSTIs has been associated with a higher risk of developing immune reconstitution inflammatory syndrome (IRIS) in some studies [144, 145]. In a recent meta-analysis, it was concluded that there was no association between INSTI regimens and risk of IRIS [146]. Due to the limitations of many of the various studies conducted, further research is needed to directly assess and understand the potential association between INSTIs and the risk of IRIS.

**Adherence**

Adherence to treatment of HIV is essential for achieving positive treatment outcomes. Numerous barriers such as adverse effects and complexity of regimens may negatively influence adherence to ART. One major advantage of COBI is its ability to be co-formulated with other ARVs allowing for reduced pill burden through the development of once daily FDC regimens. Studies have shown the benefits of using once daily ART regimens including improved rates of adherence [147, 148]. Simplicity and convenience are important factors for ensuring that individuals living with HIV have sustained and adequate adherence to lifelong ART [149]. Given that infants with HIV who weigh at least 3 kg and aged ≥ 4 weeks can use the INSTI DTG or RAL, this might help improve overall adherence to ART in this population. Furthermore, for children who can swallow, DTG has a relatively small pill size, and its pediatric formulations are even smaller in diameter.

Although the long acting CAB and RPV injections are not approved for use in treatment-naïve individuals living with HIV, it provides a favorable option to replace the current ART regimen for those individuals who have a suppressed HIV viral load, have no known or suspected resistance to CAB and RPV, and have problems taking medication on a daily basis [150]. It is important to consider, however, that individuals being considered for once monthly or every two-month injections with CAB and RPV must be counseled regarding the importance of adhering to scheduled dosing visits. Using this treatment in a patient with a history of poor clinic visit attendance may put the patient at risk of viral rebound and development of resistance with missed doses. Similarly, this should be taken into consideration prior to clinicians prescribing CAB for PrEP to help reduce the risk of acquiring HIV-1 infection and development of resistance.

**Drug-drug interactions**

Although INSTIs are generally associated with fewer DDIs compared to other ARV classes such as NNRTIs and PIs, co-administration of INSTIs with supplements containing polyvalent cations may decrease the bioavailability of INSTIs leading to potential resistance and HIV disease progression [151, 152]. Some solutions that may help to manage this DDI are to take the INSTI with food to offset the extent of the DDI or to ideally space administration of the INSTI from polyvalent cations by at least 2 h before and 6 h after supplement administration [152]. Refer to Table 2 for a comprehensive summary of DDIs between INSTIs with selected co-administered drugs. Since complementary and alternative medicine (CAM) use is common among the HIV population, it is important for clinicians to frequently ask whether patients are using CAM so that this knowledge can inform whether there are any potential DDIs with ART including INSTIs [153].

One other significant DDI to highlight is co-administration of INSTIs such as RAL and DTG with antimycobacterial tuberculosis medications including rifamycins. This is particularly important since tuberculosis co-infection is more prevalent in low- and middle-income countries and transitioning to DTG-based regimens is becoming increasingly more common in these areas [154]. Greater pill burden with twice daily dosing is required for both RAL and DTG when either is introduced together with rifampin. This dosing modification helps to compensate for reduced concentrations of RAL and DTG that can occur with strong CYP and UGT1A1 inducers such as rifampin. However, both RAL and DTG can be used simultaneously with rifabutin without any necessary dose adjustments. In general, rifamycins are not recommended when using BIC, EVG and CAB (refer to Table 2).

**Conclusions**

In conclusion, clinical trials have shown that INSTIs have excellent efficacy and favorable safety profiles compared to other ARV classes. Most INSTIs are available as once daily fixed-dose combinations offering numerous
advantages in addition to simplified, reduced pill burden, including fewer DDIs with unboosted INSTIs (RAL, DTG, BIC and CAB) and high genetic barrier to development of resistance (especially, DTG and BIC). These characteristics are critical in an aging HIV population with increasingly prevalent comorbidities and concomitant polypharmacy. The long-acting injectable formulation of CAB may also serve well for those individuals who are virologically suppressed but have difficulty remembering to take medications on a daily basis, both as treatment for HIV-1 infection as well as PrEP for those at risk of acquiring HIV. The long-term clinical implications of cumulative weight gain associated with DTG and BIC warrant further study. Certain INSTIs may be more appropriate than others depending on the clinical situation. Therefore, careful consideration of a patient’s clinical history should be made when choosing between INSTIs, especially as they continue to be more commonly used worldwide.

Declarations

Ethics approval and consent to participate
Not Applicable.

Consent for publication
Not Applicable.

Competing interests
ACM currently works for ViiV Healthcare as a Medical Science Liaison and RCG currently works for GlaxoSmithKline as an HIV Medical Information Scientist.

Author details
1Department of Pharmacy Practice and Translational Research, University of Houston, 4849 Calhoun Road Rm 3044, Houston, TX 77204-5039, USA. 2Department of Pharmacotherapy, Washington State University College of Pharmacy and Pharmaceutical Sciences, 3110 Inspiration Dr, Yakima, WA 98901, USA. 3GSK Medical Information Center of Excellence, 410 Blackwell Street, Durham, NC 27701, USA. 4Department of Pharmacy Services, UC Davis Health, 2315 Stockton Blvd, Sacramento, CA 95817, USA. 5PharmD Candidate, University of Houston College of Pharmacy, 4849 Calhoun Rd Rm 3044, Houston, TX 77204-5039, USA. 6Department of Pharmacy Practice, Temple University School of Pharmacy, 3401 N. Broad St, Philadelphia, PA 19140, USA.

Received: 1 August 2022 Accepted: 26 September 2022
Published online: 22 October 2022

Abbreviations

3TC: Lamivudine; ABC: Abacavir; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ART: Antiretroviral therapy; ARV: Antiretroviral; ATV: Atazanavir; AUC: Area under the curve; BIC: Bictegravir; BMI: Body mass index; CAB: Cabotegravir; CAM: Complementary and alternative medicine; COBI: Cobicistat; CNS: Central nervous system; CYP: Cytochrome P-450; DDI: Drug-drug interaction; DNA: Deoxyribonucleic acid; DTG: Dolutegravir; DRM: Drug resistance mutation; EFV: Efavirenz; eGFR: Estimated glomerular filtration rate (Cockcroft-Gault, mL/min); Env: HIV-1 envelope glycoprotein; EVG: Elvitegravir; FDA: Food and drug administration; FDC: Fixed-dose combination; FTC: Emtricitabine; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDL: High-density lipoprotein; HIV: Human immunodeficiency virus; IDV: Intravenous; INSTIs: Integrase strand transfer inhibitor; IRS: Immune reconstitution inflammatory syndrome; LA: Long-acting; LDL: Low-density lipoprotein; MATE: Multi-drug and toxin extrusion transporter; MOI: Multiplicity of infection; NTERT: Nucleoside reverse transcriptase inhibitor; OAT: Organic anion transporter; OCT: Organic cation transporter; PDDF: Protocol-defined virologic failure; PEP: Pre-exposure prophylaxis; RAL: Raltegravir; RAM: Resistance associated mutation; RNA: Ribonucleic acid; RPV: Rilpivirine; RTV: Ritonavir; TAF: Tenofovir alafenamide; TC: Total cholesterol; TG: Triglycerides; TDF: Tenofovir disoproxil fumarate; UGT: Uridine diphosphate glucuronosyltransferase.

Acknowledgements

We acknowledge Erica Morales, PharmD who, while a PharmD candidate, contributed to the manuscript. We appreciate her dedication to expanding her knowledge and professional development.

Author contributions

AVZ, RDC, ACM, and RCG were major contributors in writing the manuscript. TL contributed to writing the manuscript and Fig. 1 development. All authors contributed content for table and figure development. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials
Not Applicable.

References

1. WHO Guidelines Approved by the Guidelines Review Committee. In Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.

2. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultAndAdolescentGL.pdf]

3. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2:276–313.

4. EACS Guidelines version 11.0. October 2021.

5. Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, Brennan C, de Oliveira CF. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17:19490.

6. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRINT-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927–35.

7. Viani RM, Alvero C, Fenton T, Acosta EP, Hazra P, Towley E, Steimers D, Min S, Wiznia A. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015;34:1207–13.

8. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the single randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70:515–9.

9. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657–63.
10. German P, Liu HC, Szwarzberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of coadministration on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32–40.

11. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Xue W, Jin X, Ning L, Wang M, Liu H, Yao X. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model. 2013;53:210–22.

12. Lahnin CD, Xu Y, Wang K, Alvarez JA, Sheth AN, O’Halloran J, Spence AB, Tien P, Gustafson DR, Milam J, et al. Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV. AIDS Res Hum Retroviruses. 2021;37:461–7.

13. Cabenuva [package insert]. Research triangle park, NC: ViiV Healthcare; 2021. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PL-FU-FU3.PDF. Accessed 25 July 2022.

14. Biktary [package insert]. Foster City, CA: Gilead; 2021. https://www.gilead.com/~/media/files/medicines/hiv/biktarvy/biktarvy_pi.pdf. Accessed 25 July 2022.

15. Hocqueloux L, Lefeuvre S, Bois J, Valentin C, Brucato S, Alix A, Peyro-Sant-Paul I, Got L, Fournel F, Saint-Carlier E, et al. Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir / emtricitabine / tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study. Poster presented at: 18th European AIDS Conference; October 27–30, 2021; London, United Kingdom. Abstract available at: https://www.abstractserver.com/eacabstractarchive/. Accessed 26 Sept 2022.

16. Roa PE, Bazzi R. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer. Int J STD AIDS. 2022;33:97–8.

17. Roe SM, Clary JC, Drummond M, Derrick C, Sanasi K, Bookstaver PB. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: a case report and review of the literature. Am J Health Syst Pharm. 2022;79:1130–6.

18. Apretude [package insert]. Research triangle park, NC: ViiV Healthcare; 2021. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Apretude/pdf/APRETUDE-PI-PL-FU-FU.PDF. Accessed 25 July 2022.

19. Tivicay [package insert] research triangle park NG, 2013. Tivicay [package insert] research triangle park, NC: GlaxoSmithKline; 2022. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Tivicay/pdf/TVICAY-PI-PL-FU-FU.PDF#page=1. Accessed 24 Sept 2022.

20. Dovato [package insert]. Research triangle park, NC: ViiV healthcare; 2022. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Dovato/pdf/DOVATO-PI-PL-FU-PDF. Accessed 24 Sept 2022.

21. Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, Popson S, Roskam-Kwint M, Bollen P, Colbers A, Duisenberg-van Essenberg M, Kruijssen M, Abbink E, van Crevel R, Burger D. Brief report: pharmacokinetics of crushed elvitegravir combination tablet given with or without enteral nutrition. J Acquir Immune Defic Syndr. 2017;74:571–4.

22. Stribild [package insert] Foster City, CA: Gilead Sciences; 2022. https://www.gilead.com/~/media/files/medicines/hiv/genvoya/genvoya_pi.pdf. Accessed 24 Sept 2022.

23. Rossetti B, Fabbiani M, Di Carlo D, Incardona F, Gomes P, Abecasis A, Gomes P, Barreca ML, Ferro S, Rao A, De Luca L, Zappalà M, Monforte AM, Debyser V, Psevdos G. Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, coformulated emtricitabine, and tenofovir alafenamide. Am J Health Syst Pharm. 2014;71(84):786.

24. Kaplan O, Psevdos G. Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, coformulated emtricitabine, and tenofovir alafenamide. Am J Health Syst Pharm. 2019;76:1180–1.

25. Jongbloed-de Hoorn M, Colbers A, Velthoven-Graafland K, Duisenberg-van Essenber M, Kruisjes M, Abbink E, van Crevel R, Burger D. Brief report: pharmacokinetics of crushed elvitegravir combination tablet given with or without enteral nutrition. J Acquir Immune Defic Syndr. 2017;74:571–4.

26. Juluca [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2022. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Juluca/pdf/JULUCA-PI-PL-FU-PDF#page=1. Accessed 24 Sept 2022.

27. Triumeq [package insert] Research Triangle Park, NC: ViiV Healthcare; 2022. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-FU-PDF#page=1. Accessed 24 Sept 2022.

28. Genvoya [package insert] Foster City, CA: Gilead Sciences, Inc; 2022. https://www.gilead.com/~/media/files/medicines/hiv/genvoya/genvoya_pi.pdf. Accessed 24 Sept 2022.

29. Fallo P, Ayala-Sims VA. Sustained virological response after taking crushed elvitegravir-coformulated emtricitabine-tenofovir tablets. Am J Health Syst Pharm. 2014;71(84):786.
integrate-inhibitor-naïve adults with HIV-1 infection. 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83:310–8.

96. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet. 2019;393:143–55.

97. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brai D, Daar ES, Wold H, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1490): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063–72.

98. Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus ES, Stellbrink HJ, Antinori A, Workovski K, Slim J, Raynes J, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073–82.

99. Orkin C, Arasteh K, Gorgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walsmsley S, Bettacchi C, Brinson C, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1121–35.

100. Swindells S, Andrade-Villanueva JF, Richmond GL, Rizzardi G, Baumgartner A, Masini M, Latif G, Pokrovsky V, Bredenk F, Smith G, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–23.

101. Santos JR, Saumoy M, Currán A, Bravo I, Lilley JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403–8.

102. Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink H-J, Wold H, Mazzolli F. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The Lancet. 2020;390:4389–400.

103. Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen G, Garcia JG, Morell EB, Tan DHS, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet. 2021;388:1853–66.

104. Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, et al. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36:185–94.

105. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Hoelz L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595–608.

106. Delany-Moretwe S, Hughes JR, Bock P, Ouma SG, Hnudzirna P, Kalonji E, Kayange N, Makheha J, Mandima P, Mathew C, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779–89.

107. Rockstroh JK, DeJesus E, Lenzon J, Zaidanparan Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNobile MJ, et al. Durable efficacy and safety of raltegravir versus rilpivirine when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMARC. J Acquir Immune Defic Syndr. 2013;63:77–85.

108. Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance: a meta-analysis of 17 randomized controlled trials. Retrovirology. 2017;14:36.

109. Psichogiu M, Poulakou G, Basoulis D, Paraskevis D, Markogiannakis A, Daikos GL. Current advances in antiretroviral agents: potent integrase inhibitors. Curr Pharm Des. 2017;23:2552–67.

110. Gallant JE, Thompson M, DeJesus E, Voskuil GW, Wei X, Zhang H, White K, Cheng A, Quirk E, Martin H. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;75:61–6.

111. Lilley JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahi LP, Blair EA, Angeli K, Wyne B, Vandermeulen K, et al. Efficacy, safety, and tolerability of dolutegravir–rilpivirine for the maintenance of virological...
suppression in adults with HIV-1: phase 3, randomised, non-inferiority
SOFTWARE-1 and SOFTWARE-2 studies. Lancet. 2018;391:839–49.

112. Parentti JI, Fournier AL, Cotte L, Schneider MP, Etienne M, Unal G, Penet P, Dutheil JJ, Morilland-Lecoq E, Chailot F, et al. Forgiveness of
dolutegravir-based triple therapy compared with older antiretroviral
regimens: a prospective multicenter cohort of adherence patterns and
HIV-RNA replication. Open Forum Infect Dis. 2021. https://doi.org/10.
1093/ofid/ofab316.

113. Sax PE, Rockstroh JK, Luerkmeier AF, Yadzandepanah Y, Ward D, Trotter B, Rieger A, Liu H, Acosta R, Collins SE, et al. Switching to bica-
vertic, emtricitabine and tenofovir alafenamide in virologically sup-
pressed adults with human immunodeficiency virus. Clin Infect Dis.
2021;73:e485–93.

114. Bam RA, Yant SR, Chihlar T. Tenofovir alafenamide is not a substrate for
renal organic anion transporters (OATs) and does not exhibit OAT-
dependent cytotoxicity. Antivir Ther. 2014;19:687–92.

115. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofo-
vir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a
randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–8.

116. Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya Kauppinen KJ, Kivelä P, Sutinen J. Switching from tenofovir disoproxil
emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25:1881–6.

118. Gallant JE, Koenig E, Andrade-Villanueva JF, DeJesus Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Vanveggel S, Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown Ursenbach A, Max V, Maurel M, Bani-Sadr F, Gagneux-Brunon A, Garraffo R, Ravaj I, Robineau O, Makinson A, Reid D. Incidence of
diabetes in HIV-infected patients treated with first-line integrase strand
inhibitors: a French multicentre prospective study. J Antimicrob Chemother. 2020;75:3344–8.
In 13th international workshop on HIV pediatrics: 11th IAS conference on HIV science; July; virtual meeting. 2021.

143. Llibre JM, Martinez-Picado J. Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment. Enferm Microbiol Clin. 2008;26(Suppl 12):17–22.

144. Gaillet A, Calin R, Flandre P, Tubiana R, Valantin MA, Caumes E, Katlama C, Pourcher V. Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving integrase inhibitors. Infect Dis Now. 2021;51:90–3.

145. Psychogiosi M, Basoulis D, Tsikala-Vafea M, Vlachos S, Kapelios CJ, Daikos GL. Integrase strand transfer inhibitors and the emergence of immune reconstitution inflammatory syndrome (IRIS). Curr HIV Res. 2017;15:405–10.

146. Zhao Y, Hohlfeld A, Namale P, Meintjes G, Maartens G, Engel ME. Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2022;90:232–9.

147. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68:567–78.

148. Sweet D, Song J, Zhong Y, Signorovitch J. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment. J Int AIDS Soc. 2014;17:19537.

149. Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV AIDS (Auckl). 2016;8:47–65.

150. Cabenuva [package insert]. Research Triangle Park, NC: VIIV Healthcare. 2021.

151. Griessinger JA, Hauptstein S, Laffleur F, Netsomboon K, Bernkop-Schnürch A. Evaluation of the impact of multivalent metal ions on the permeation behavior of Dolutegravir sodium. Drug Dev Ind Pharm. 2016;42:1118–26.

152. Song J, Borland J, Arya N, Wynne B, Piscitelli S. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55:490–6.

153. Bahall M. Prevalence, patterns, and perceived value of complementary and alternative medicine among HIV patients: a descriptive study. BMC Complement Altern Med. 2017;17:422.

154. Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, Ripin D, Flexner C, Domanico PL. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32:1351–61.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.